Pacific Booker Minerals Inc Ordinary Shares PBM 深 沪
已收盘 12-19 16:00:00 美东时间
1.00
-0.460
-31.51%
华盛通- 最 高1.47
- 今 开1.44
- 成交量 3463.79万股
- 最 低 0.97
- 昨 收 1.46
- 总市值 58.33万
- 52周最高 18.4394
- 市盈率 静 0.56
- 换手率 5.94%
- 52周最低 0.97
- 委 比 -48.85%
- 总股本 58.33万
- 历史最高 62.7239
- 量 比 175.15
- 振 幅 34.25%
- 历史最低 0.97
- 每 手 1
- 风险率 4.23%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Market-Moving News for December 19th
NKE: -10% | Nike shares are trading lower. The company reported a 17% decline in Greater China sales in Q2. KBH: -7% | KB Home shares are trading lower. The company reported Q4 financial results. PBM:
12-19 20:21
Psyence BioMed shares are trading higher after the CEO's year-end letter highlighted progress on its Phase IIb psilocybin trial, ethical ibogaine sourcing in Africa, and its cash position.
Psyence BioMed shares are trading higher after the CEO's year-end letter highli...
12-09 20:58
Psyence Secures Long-Term Supply Of Plant-Based Drug Ingredient For Addiction Treatment Research, Moves Closer To Clinical Trials With New Source Of Ibogaine For Substance Use Therapies
Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today
11-20 20:10
Psyence BioMed Expands Through PsyLabs, Establishing Exclusive Public Market Presence In Africa For Ibogaine & Psilocybin Development
Psyence BioMed (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced that, through its
11-12 20:12
Psyence Biomedical Makes $3.50M Follow-On Investment In PsyLabs
Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and Ibogaine therapies for unmet mental health needs, today announced it has made
11-03 20:20
A Peek at Cigna Group's Future Earnings
Cigna Group (NYSE:CI) is gearing up to announce its quarterly earnings on Thurs...
10-29 22:01
Novartis Maintains Outlook Even As Generics Bite Into Profits
Novartis Q3 sales rose 8% to $13.91 billion, missing estimates, as Kisqali and Kesimpta drove growth while U.S. generics weighed on results.
10-28 18:58
UnitedHealth stock rises on Q3 beats, raised guidance
UnitedHealth (NYSE:UNH) shares rose in the premarket on Tuesday after the managed care giant beat Wall Street expectations with its Q3 results and raised its full-year earnings outlook. Shares of the ...
10-28 18:11
Cigna eliminating drug rebates for PBM clients starting in 2027
Cigna (NYSE:CI) said that its health services division, Evernorth, which includes the pharmacy benefit manager Express Scripts, will eliminate the controversial practice of drug rebates for all of its...
10-28 03:18
Market Voices: Cigna's PBM move, Bessent on Fed chair, Lululemon-NFL
Seeking Alpha's roundup of statements, announcements, and remarks that could impact markets, sectors, or individual stocks. Cigna (NYSE:CI) plans to phase out drug rebates for its commercial healthcar...
10-27 23:47
